Q-omics provides the consensus-scored DEFB131B profile across patient tissues and cancer cell-line models. DEFB131B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, DEFB131B is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, DEFB131B RNA expression shows 19,015 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight READ, HNSC, and KIRP as cancer lineages where DEFB131B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB131B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB131B survival associations across molecular data types. DEFB131B RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB131B RNA expression–survival associations across cancer types. High DEFB131B expression shows unfavorable associations in ACC, but favorable associations in READ, SKCM, BRCA, LUSC and OV. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for DEFB131B RNA expression.
This table summarizes DEFB131B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for DEFB131B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFB131B shows lower tumor expression in THCA and higher tumor expression in HNSC, STAD, CHOL, LIHC and LUAD. The HNSC box plot shows higher DEFB131B RNA expression in tumor versus normal tissue (log2 FC = +0.254, t-test p = .006).
This table shows molecular features associated with DEFB131B in patient tissues and cancer cell lines. In patient samples, DEFB131B shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, DEFB131B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD.
